文献速递乳腺癌

细胞毒性肿瘤浸润淋巴细胞在预测转移性HER2阳性乳腺癌结局中的作用:一项随机临床试验的二次分析

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2017-11-09

该研究为MA.31 III期试验的二次分析,纳入652例转移性HER2阳性乳腺癌患者,随机接受曲妥珠单抗或拉帕替尼联合紫杉类治疗。高H&E间质TILs(>5%)未见显著预后或预测效应;低CD8+间质TILs患者中拉帕替尼较曲妥珠单抗进展风险更高(HR 2.94),高CD8+组亦高(HR 1.36),交互作用P=0.04。结论:低水平细胞毒性间质TILs预示抗体类药物较小分子药物获益更大。

要点

  • 高H&E间质TILs(>5%)在转移性HER2阳性乳腺癌中未见显著预后或预测效应。
  • 低CD8+间质TILs患者中,拉帕替尼较曲妥珠单抗进展风险更高(HR 2.94,95%CI 1.40-6.17,P=0.003)。
  • 高CD8+间质TILs患者中,拉帕替尼较曲妥珠单抗进展风险亦更高(HR 1.36,95%CI 1.05-1.75,P=0.02),交互作用P=0.04。

核心结论

  • 在转移性HER2阳性乳腺癌中,低水平预存的细胞毒性间质TILs预示抗体类药物较小分子药物获益更大。

研究设计与样本

  • 加拿大癌症试验组MA.31 III期随机临床试验的二次分析,2008年1月17日至2011年12月1日从21个国家入组652例转移性HER2阳性乳腺癌患者。
  • 患者随机接受曲妥珠单抗或拉帕替尼联合紫杉类(紫杉醇或多西他赛)治疗24周,既往未接受过转移灶化疗或HER2靶向治疗。
  • 中位随访21.5个月(四分位距14.3-31.0),采用诊断时肿瘤组织进行H&E染色评估间质TILs,并行免疫组化评估CD8、FOXP3、CD56和PD-1表达。
  • 647例接受治疗女性中,614例有H&E间质TILs评分,427例有CD8生物标志物评估。

主要发现

  • H&E间质TILs>5%(高)者215例(35%),未显示显著预后或预测效应。
  • 低CD8+间质TILs患者中,拉帕替尼较曲妥珠单抗进展风险更高(观察HR 2.94,95%CI 1.40-6.17,P=0.003)。
  • 高CD8+间质TILs患者中,拉帕替尼较曲妥珠单抗进展风险亦更高(观察HR 1.36,95%CI 1.05-1.75,P=0.02)。
  • 逐步多变量分析确认交互作用P=0.04;其他免疫组化标志物未显示预后或预测效应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Accumulating evidence indicates that tumor-infiltrating lymphocytes (TILs) are associated with clinical outcomes and may predict the efficacy of chemotherapy and human epidermal growth factor receptor 2 (HER2, encoded by the gene ERBB2)-targeted therapy in patients with HER2-positive breast cancer. OBJECTIVE: To investigate the role of TILs, particularly cytotoxic CD8+ T cells, in the prediction of outcomes in patients with HER2-positive metastatic breast cancer randomized to an antibody-based (trastuzumab) vs a small molecule-based (lapatinib) anti-HER2 therapy. DESIGN, SETTING, AND PARTICIPANTS: The Canadian Cancer Trials Group MA.31 phase 3 clinical trial accrued patients from 21 countries and randomized 652 with HER2-positive metastatic breast cancer to receive trastuzumab or lapatinib, in combination with a taxane, from January 17, 2008, through December 1, 2011. Patients had received no prior chemotherapy or HER2-targeted therapy in the metastatic setting. The median follow-up was 21.5 months (interquartile range, 14.3-31.0). The tumor tissue collected for primary diagnosis was used in this ad hoc substudy. Sections were scored for TILs on hematoxylin-eosin (H&E)-stained sections, and immunohistochemical analysis was performed to assess CD8, FOXP3, CD56, and programmed cell death protein 1 (PD-1) expression on stromal (sTILs) and intratumoral TILs. Data were analyzed from July 15, 2015, through July 27, 2016. INTERVENTIONS: Treatment with trastuzumab or lapatinib in combination with taxane chemotherapy (paclitaxel or docetaxel) for 24 weeks. MAIN OUTCOMES AND MEASURES: Prognostic effects of biomarkers were evaluated for progression-free survival by stratified univariate log-rank test with Kaplan-Meier curves and by multivariate Cox proportional hazards regression; predictive effects were examined with a test of interaction between treatment allocation and biomarker classification. RESULTS: Of the 647 treated women (mean [SD] age, 55.0 [10.8] years), 614 had tumor tissue samples scored for H&E sTILs and 427 for CD8 biomarker assessments. Overall H&E sTIL counts of greater than 5% (high) were present in 215 cases (35%) but did not show significant prognostic or predictive effects. Univariate stratified analyses detected a significant predictive effect on risk for progression with lapatinib compared with trastuzumab among patients with low CD8+ sTIL counts (observed hazard ratio, 2.94; 95% CI, 1.40-6.17; P = .003) and among those with high CD8+ sTIL counts (observed hazard ratio, 1.36; 95% CI, 1.05-1.75; P = .02), confirmed in stepwise multivariate analysis (interaction P = .04). Other immunohistochemistry biomarkers were not associated with prognostic or predictive effects. CONCLUSIONS AND RELEVANCE: In this secondary analysis of a phase 3 randomized clinical trial, a low level of preexisting cytotoxic sTILs predicted the most benefit from an antibody- vs a small molecule-based drug against the same target. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00667251.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Liu S, Chen B, Burugu S, et al. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 28750133. doi:10.1001/jamaoncol.2017.2085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。